Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by brad129on Aug 15, 2022 10:45pm
198 Views
Post# 34898308

RE:RE:RE:RE:...AND WE'RE OFF TO THE RACES

RE:RE:RE:RE:...AND WE'RE OFF TO THE RACES

tests direct are $1500 US, things are improving dramatically, break even in this field is substantial and the big target. Once that taget is hit (and I believe we are there today) financing will come through. Once in the black there will be cash for company promotion and that's when the ball starts rolling. Marketing is key for the successful company to spread the word. Hard to promote when under severe cash restraints. 



frewil11 wrote: With a Aristotle test costing close to 3000 dollars , 100 tests performed would be around 300k revenue , I might be wrong but there basically not even testing , for many years when they release news just before a CC , its fluff , so why this time you seem sure it will be different . 

 

<< Previous
Bullboard Posts
Next >>